PT1012154E - Sais de di(5'-tetrafosfato de uridina), metodo para a sua preparacao, e suas utilizacoes - Google Patents

Sais de di(5'-tetrafosfato de uridina), metodo para a sua preparacao, e suas utilizacoes

Info

Publication number
PT1012154E
PT1012154E PT98937115T PT98937115T PT1012154E PT 1012154 E PT1012154 E PT 1012154E PT 98937115 T PT98937115 T PT 98937115T PT 98937115 T PT98937115 T PT 98937115T PT 1012154 E PT1012154 E PT 1012154E
Authority
PT
Portugal
Prior art keywords
sub
treatment
utilizations
preparing
preparation
Prior art date
Application number
PT98937115T
Other languages
English (en)
Inventor
Benjamin R Yerxa
William Pendergast
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of PT1012154E publication Critical patent/PT1012154E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT98937115T 1997-07-25 1998-07-24 Sais de di(5'-tetrafosfato de uridina), metodo para a sua preparacao, e suas utilizacoes PT1012154E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5414797P 1997-07-25 1997-07-25

Publications (1)

Publication Number Publication Date
PT1012154E true PT1012154E (pt) 2004-08-31

Family

ID=21989063

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98937115T PT1012154E (pt) 1997-07-25 1998-07-24 Sais de di(5'-tetrafosfato de uridina), metodo para a sua preparacao, e suas utilizacoes

Country Status (16)

Country Link
US (1) US7432252B1 (pt)
EP (1) EP1012154B1 (pt)
JP (1) JP3723227B2 (pt)
KR (1) KR20010013797A (pt)
CN (1) CN1147502C (pt)
AT (1) ATE261982T1 (pt)
AU (1) AU747196B2 (pt)
BR (1) BRPI9810436B1 (pt)
CA (1) CA2295515C (pt)
DE (1) DE69822482T2 (pt)
DK (1) DK1012154T3 (pt)
ES (1) ES2217569T3 (pt)
NO (1) NO328229B1 (pt)
NZ (1) NZ501696A (pt)
PT (1) PT1012154E (pt)
WO (1) WO1999005155A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6872710B2 (en) 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
ATE261982T1 (de) 1997-07-25 2004-04-15 Inspire Pharmaceuticals Inc Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
NZ510748A (en) * 1998-10-02 2002-10-25 Yamasa Corp Crystal of diuridine tetraphosphate or salt thereof
CN100354296C (zh) * 1998-10-02 2007-12-12 雅玛山酱油株式会社 二尿苷四磷酸或其盐的晶体和其制备方法、以及制备该化合物的方法
AU767136B2 (en) * 1999-06-30 2003-10-30 Merck Sharp & Dohme Corp. Dinucleotide crystals
WO2001056581A1 (en) * 2000-02-04 2001-08-09 Kissei Pharmaceutical Co., Ltd. Powdered preparation for inhalation and powder inhalant containing the same packed
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
CN1228053C (zh) * 2001-09-11 2005-11-23 参天制药株式会社 含有二尿苷磷酸的滴眼液
KR100870104B1 (ko) * 2005-11-28 2008-11-26 주식회사 머젠스 안구건조증 치료 및 예방용 조성물
KR101406102B1 (ko) 2006-07-26 2014-06-11 야마사 쇼유 가부시키가이샤 디(피리미딘 뉴클레오시드 5'-)폴리포스페이트의 제조방법
WO2010150791A1 (ja) * 2009-06-23 2010-12-29 ヤマサ醤油株式会社 アデノシンテトラホスフェート化合物の製造法
EA026680B1 (ru) 2010-09-10 2017-05-31 Сантен Фармасьютикал Ко., Лтд. Средство для лечения синдрома сухого глаза, характеризующееся комбинированием агониста рецептора p2yи гиалуроновой кислоты или ее соли, способ лечения синдрома сухого глаза и применение агониста рецептора p2yи гиалуроновой кислоты или ее соли
US20140221306A1 (en) 2010-12-28 2014-08-07 Santen Pharmaceutical Co. Ltd Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
CN102146111A (zh) * 2011-01-26 2011-08-10 北京润德康医药技术有限公司 一类新型二核苷酸化合物及其制备方法
EA028848B1 (ru) 2012-03-26 2018-01-31 Сантен Фармасьютикал Ко., Лтд. Офтальмологический раствор, содержащий диквафасол
CA3039053C (en) * 2016-10-25 2021-04-20 Yamasa Corporation Method for purifying p1,p4-di(uridine 5'-)tetraphosphate
KR102504764B1 (ko) 2017-06-21 2023-03-02 주식회사 종근당 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
CN109305991B (zh) * 2017-07-27 2021-02-26 江苏恒瑞医药股份有限公司 一种p1,p4-二(尿苷5’-)四磷酸钠的制备方法
KR20180091689A (ko) 2017-11-06 2018-08-16 주식회사 종근당 무정형 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
SG11202007977RA (en) 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
CN110540555B (zh) * 2018-05-28 2023-01-24 江苏恒瑞医药股份有限公司 一种游离核苷磷酸的方法
CN109021049B (zh) * 2018-06-14 2020-12-08 扬子江药业集团北京海燕药业有限公司 一种尿苷5′-二磷酸-苯并咪唑二钠的合成方法
TWI833913B (zh) 2019-02-27 2024-03-01 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、乙烯系高分子及纖維素系高分子之眼科用組合物
KR20200106738A (ko) 2019-03-05 2020-09-15 주식회사 파마코스텍 P1,p4-디(우리딘 5'-)테트라포스페이트, 이의 염 또는 이의 수화물의 신규한 제조방법
CN110590887B (zh) * 2019-09-04 2020-12-15 江苏金殳医药科技有限公司 一种磷酸酯的制备方法
KR102790402B1 (ko) 2019-12-18 2025-04-03 주식회사 종근당 우리딘 5’-디인산(udp), 이의 염 또는 이의 수화물의 제조방법
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법
CN111662350B (zh) * 2020-07-07 2022-06-07 南京宸翔医药研究有限责任公司 一种绿色化智能化高纯度地夸磷索四钠的制备方法
CN114644664A (zh) * 2020-12-18 2022-06-21 齐鲁制药有限公司 一种制备对称双尿苷四磷酸盐的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639561A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US3639562A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
JPH05346549A (ja) 1992-04-17 1993-12-27 Canon Inc 走査光学装置
WO1995010538A1 (en) 1993-10-15 1995-04-20 The University Of North Carolina At Chapel Hill Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
JP3519199B2 (ja) 1996-02-06 2004-04-12 株式会社ソニー・コンピュータエンタテインメント 画像生成装置
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US5837861A (en) 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5900407A (en) * 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
WO1997035591A2 (en) * 1996-03-27 1997-10-02 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
US5962432A (en) 1996-07-03 1999-10-05 Inspire Pharmaceuticals, Inc. Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US5968913A (en) 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5789391A (en) 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998015835A1 (en) 1996-10-08 1998-04-16 Inspire Pharmaceuticals, Inc. Method of early lung cancer detection via sputum induction and analysis of sputum to detect cancer associated substances
US6159952A (en) 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
EP0981534B1 (en) * 1997-02-06 2006-05-03 Inspire Pharmaceuticals, Inc. Dinucleotides and their uses
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
ATE261982T1 (de) 1997-07-25 2004-04-15 Inspire Pharmaceuticals Inc Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
CA2300146A1 (en) 1997-08-29 1999-03-04 Richard C. Boucher, Jr. Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
DE69905464T2 (de) 1998-05-22 2004-01-15 Inspire Pharmaceuticals Inc Therapeutische dinucleotide und deren derivate
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
GB9827477D0 (en) 1998-12-15 1999-02-10 Kalon Limited Paint
CA2355227A1 (en) 1998-12-23 2000-07-06 Richard C. Boucher, Jr. Targeted gene transfer using g protein coupled receptors
JP2002537329A (ja) 1999-02-26 2002-11-05 インスパイアー ファーマシューティカルズ，インコーポレイティド 特定のウリジン、アデニン及びシチジン二リン酸並びにそれらの類似体による粘膜水和の促進方法

Also Published As

Publication number Publication date
EP1012154A2 (en) 2000-06-28
WO1999005155A3 (en) 1999-06-24
NO328229B1 (no) 2010-01-11
NO996189D0 (no) 1999-12-14
NO996189L (no) 2000-03-27
BR9810436A (pt) 2000-12-12
CN1265114A (zh) 2000-08-30
US7432252B1 (en) 2008-10-07
CN1147502C (zh) 2004-04-28
AU747196B2 (en) 2002-05-09
HK1028613A1 (en) 2001-02-23
DK1012154T3 (da) 2004-07-26
ES2217569T3 (es) 2004-11-01
CA2295515A1 (en) 1999-02-04
ATE261982T1 (de) 2004-04-15
KR20010013797A (ko) 2001-02-26
WO1999005155A2 (en) 1999-02-04
DE69822482T2 (de) 2005-03-03
JP3723227B2 (ja) 2005-12-07
NZ501696A (en) 2001-08-31
CA2295515C (en) 2006-03-14
AU8590398A (en) 1999-02-16
BRPI9810436B1 (pt) 2015-12-29
JP2001510484A (ja) 2001-07-31
DE69822482D1 (de) 2004-04-22
EP1012154B1 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
PT1012154E (pt) Sais de di(5'-tetrafosfato de uridina), metodo para a sua preparacao, e suas utilizacoes
WO2000030629A3 (en) Method of promoting cervical and vaginal secretions
BR9809562A (pt) Método de tratar doença de secura ocular com agonistas receptores purinérgicos
BR0206492A (pt) Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células
BR0011854A (pt) Agonistas de receptores de a2a de c-pirazola
NZ522326A (en) Adenosine A2A receptor antagonists
YU76100A (sh) Pirolo(2,3-d) pirimidin preparati i njihova primena
LU92425I2 (fr) Dichlorure de radium Ra 2232 et ses dérivés pharmaceutiquement acceptables (XOFIGO®)
KR20050047536A (ko) 질 건강 제품
PT1137409E (pt) Composicoes e metodos para melhoramento da disfuncao sexual feminina humana
BR9610059A (pt) Método para detectar doença pulmomar
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
TR200002218T2 (tr) 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri
ATE307136T1 (de) Agonisten für den adenosin a3 rezeptor
PE20000939A1 (es) Formulaciones de fsh y variantes de fsh, productos y metodos
BR0112659A (pt) Processo para o tratamento de secura vaginal ou disfunção sexual em mulheres durante ou depois da menopausa e utilização do composto (diaminoidroxi)toremifeno ou de um sal, éster ou metabolito farmaceuticamente aceitável do mesmo
DK468288D0 (da) Antivirale forbindelser
BR9812404A (pt) Combinação de um antagonista de endotelina, preparação farmacêutica, processo para preparar uma preparação farmacêutica, e , uso de uma combinação de um bloqueador de beta receptor e de um antagonista de endotelina
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
BR9710206A (pt) Uso de um agente de interleucina-8 e formulação farmacéutica antiviral
AP2004003082A0 (en) Pharmaceutical combinations of adenosine A-2A and beta-2- adrenergic receptor agonists
IT1251160B (it) Impiego di composti adenosinici nel trattamento dell'ischemia
BR9811422A (pt) Processo para a inibição de hiperplasia celular de músculo liso vascular em um paciente humano ou em outro paciente animal de sangue quente necessitando de tal tratamento, uso de pelo menos um oligossacarìdeo sulfatado, e, composição farmacêutica ou veterinária para a inibição de hiperplasia celular de músculo liso vascular
DE60008589D1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
BR0005319A (pt) Tratamento combinado para depressão e ansiedade